Quotes 5-day view Real-time Euronext Paris
01/22/2021
01/25/2021
01/26/2021
01/27/2021
01/28/2021
Date
81.46(c)
81.5(c)
81.07(c)
79.07(c)
78.87 Last
2 012 106
1 820 478
2 053 028
3 352 652
607 930 Volume
+0.05% +0.05% -0.53% -2.47% -0.25% Change
Sales 2020
36 746 M 44 419 M 44 419 M
Net income 2020
10 246 M 12 386 M 12 386 M
Net Debt 2020
8 676 M 10 487 M 10 487 M
P/E ratio 2020
8,51x
Yield 2020
4,08%
Sales 2021
37 521 M 45 355 M 45 355 M
Net income 2021
5 541 M 6 698 M 6 698 M
Net Debt 2021
6 355 M 7 682 M 7 682 M
P/E ratio 2021
17,7x
Yield 2021
4,22%
Capitalization
99 342 M 120 B 120 B
EV / Sales 2020
2,94x
EV / Sales 2021
2,82x
Nbr of Employees
100 409
Free-Float
88,9%
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (84.1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies, etc. Moreover, Sanofi-Aventis markets OTC products and generic drugs;
- human vaccines (15.9%): pediatric vaccines,...
Notations Surperformance© of Sanofi
Trading Rating : Investor Rating :
News in other languages on SANOFI
Analyst Recommendations on SANOFI
SANOFI - 2020
Good timing to go long again
BUY
Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SANOFI
Short Term Mid-Term Long Term Trends Neutral Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
28
Average target price
100,38 €
Last Close Price
79,07 €
Spread / Highest target
48,0%
Spread / Average Target
26,9%
Spread / Lowest Target
-11,5%
Please enable JavaScript in your browser's settings to use dynamic charts.
1st jan. Capitalization (M$)
SANOFI 0.47% 120 167
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
